- Home
- BC vs RARE Comparison
BC vs RARE Comparison
Compare BC & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BC
- RARE
- Stock Information
- Founded
- BC 1845
- RARE 2010
- Country
- BC United States
- RARE United States
- Employees
- BC N/A
- RARE N/A
- Industry
- BC Homebuilding
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- BC Consumer Discretionary
- RARE Health Care
- Exchange
- BC Nasdaq
- RARE Nasdaq
- Market Cap
- BC 4.9B
- RARE 5.2B
- IPO Year
- BC N/A
- RARE 2014
- Fundamental
- Price
- BC $66.71
- RARE $43.98
- Analyst Decision
- BC Buy
- RARE Strong Buy
- Analyst Count
- BC 14
- RARE 14
- Target Price
- BC $88.31
- RARE $88.43
- AVG Volume (30 Days)
- BC 664.8K
- RARE 717.6K
- Earning Date
- BC 01-30-2025
- RARE 02-13-2025
- Dividend Yield
- BC 2.52%
- RARE N/A
- EPS Growth
- BC N/A
- RARE N/A
- EPS
- BC 4.01
- RARE N/A
- Revenue
- BC $5,444,100,000.00
- RARE $522,745,000.00
- Revenue This Year
- BC N/A
- RARE $27.36
- Revenue Next Year
- BC $3.94
- RARE $18.61
- P/E Ratio
- BC $15.61
- RARE N/A
- Revenue Growth
- BC N/A
- RARE 27.44
- 52 Week Low
- BC $66.41
- RARE $37.02
- 52 Week High
- BC $99.68
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- BC 21.72
- RARE 33.50
- Support Level
- BC $76.45
- RARE $41.45
- Resistance Level
- BC $73.30
- RARE $50.00
- Average True Range (ATR)
- BC 2.34
- RARE 1.83
- MACD
- BC -1.14
- RARE -0.31
- Stochastic Oscillator
- BC 2.16
- RARE 26.55
About BC Brunswick Corporation
Brunswick is a leading manufacturer in the marine recreation industry. The firm has more than 60 brands delivering products across propulsion (outboard, sterndrive, and inboard engines, propulsion-related controls, rigging, and propellers), parts, accessories, and technology, and boats (including well-known brands like Boston Whaler and Sea Ray). It also owns numerous Freedom Boat Club (shared ownership) locations as well as Boateka, which facilitates transactions in the used boat market. Brunswick's focus surrounds building the innovative marine and recreational experiences, technologies, and connections supported by quality and innovation.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.